Biopharma AI
ByHow Are Biopharma Giants Deploying Agentic AI to Revolutionize R&D Over the Next 5 Years?
This executive update expands on majors like Lilly, BMS, Pfizer, GSK, Novo, plus Roche, Merck, Sanofi, and AstraZeneca,…
Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge
Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…
AbbVie’s $380M North Chicago API Expansion—300 Jobs, AI Boost for Neuroscience/Obesity Pipeline
Published by BioNextAI Media – AbbVie is injecting $380 million into two new active pharmaceutical ingredient (API) facilities at…
Pfizer’s 1,200-GPU AI Blitz—$500M Bet to Slash 18-24 Month Timelines Across Pharma Value Chain
Published by BioNextAI Media – Pfizer is deploying over 1,200 NVIDIA H100/H200 GPUs in a $500-600 million infrastructure overhaul,…
Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
DeepSeek AI Hits Hundreds of Hospitals: Pathology Revolution or Urban Elite Tool?
DeepSeek chatbot expanded to hundreds of hospitals across Shanghai, Shenzhen, and Chengdu on March 2, 2026—processing 3,000 pathology…
